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Objectives.The aim of this study was to evaluate the association between interleukin (IL)-6 and IL-10 gene polymorphism
and the short-term risk of postoperative cardiovascular events in patients with peripheral artery disease receiving elective
surgery and also to evaluate the endothelial function.
Methods and results. We determined preoperatively IL-6 gene polymorphism (-174 G/C and nt565 G/A), IL-10
polymorphism (-1082G/A, -819C/T, -592C/A), and brachial artery vasodilatation using ultrasound in 48 patients
undergoing vascular surgery. Eight patients (16.7%) developed over a period of 30 days cardiovascular events (cardio-
vascular death, resuscitated cardiac arrest, acute myocardial infarction, unstable angina, stroke). Cardiovascular events
were more frequent in the subgroups of patients with genotypes associated with high serum levels of IL-6: -174CC
(57.14% vs 12.5% for -174GC genotype and 8% for -174GG, P  .007) and nt565AA (50% vs 17.6% for nt565GA
genotype and 8% for nt565GG genotype, P  .021) and in subgroups with haplotypes associated with low serum levels
of IL-10: ATA (57.14% vs 14.8% for haplotype ACC and 7.4% for GCC, GCA, GTA, GTC haplotypes, P  .004).
Flow-mediated dilatation was significantly lower in patients with IL-6 -174CC genotype (7.05%  1.49% vs 8.41% 
1.9% for IL-6 -174GC and 9.42%  2.46% for IL-6 -174GG, P  .009) and IL-6 nt565AA genotype (7.14  1.61% vs
8.49%  1.91% for IL-6 nt565GA and 9.42%  2.46% for IL-6 nt565GG, P  .018) and in patients with IL-10ATA
haplotype (6.45% 0.57% vs 9.13% 2.52% for IL-10ACC and 9.24% 2.09% for IL-10 GCC/GCA/GTA/GTC, P
.004) respectively.
Conclusions. IL-6 -174CC and nt565AA genotypes and IL-10ATA haplotypes are correlated with a high short-term risk
of acute postoperative cardiovascular events in patients with peripheral artery disease receiving elective surgical
revascularization and with endothelial dysfunction in these patients. ( J Vasc Surg 2010;52:103-9.)Inflammation plays a central role in atherosclerotic
lesion development and progression and also in the transi-
tional phase to unstable plaque, accompanied by subse-
quent events (acute myocardial infarction, unstable angina,
cerebral vascular accident). In prospective studies, high
basal plasma levels of interleukin (IL)-6, with proinflamma-
tory and procoagulant effects, proved to be predictive for
acute cardiovascular events (AMI, unstable angina).1-3 Fur-
thermore, the Edinburgh Artery Study, which evaluated
the markers of inflammation as predictors for the peripheral
artery disease (PAD) progression estimated by the ankle-
arm index, showed that high basal serum levels of IL-6 are
associated with the progression of peripheral atheroscle-
rotic lesions over 5 years.4
It was demonstrated that high, intermediary, and low
levels of proinflammatory (IL-1, IL-6, TNF-, INF-, etc) as
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doi:10.1016/j.jvs.2010.01.088well as anti-inflammatory cytokines (IL-10) are influenced
along with the environmental factors (as infection, inflam-
mation, etc) as well as by genetic factors. Thus, genetic
variants of interleukin genes IL-6 and IL-10 were associ-
ated with plasma concentrations of interleukins5,6 and with
the risk of cardiovascular diseases (coronary disease, aortic
aneurysm).7,8 Experimental studies identified IL-6 gene
promoter polymorphism at the sites of -174 G/C, -572
G/C, -598G/A, -628C/A, -373An/Tn, and nt565 G/A,
respectively, with a low frequency of the C and A allele.9
Several authors5,8 revealed high serum values for IL-6 at
-174 CC homozygotes, compared with -174 GG homozy-
gotes and -174GC heterozygotes in patients with cardio-
vascular disease.
Also, the polymorphism of the IL-10 gene regulatory
region was identified, at the loci -1082 G/A, -819 C/T,
and -592C/A.10 High serum levels of IL-10, which are
protective against atherogenesis, were found in GCC,
GCA, GTA, and GTC haplotypes and also intermediary
serum levels of IL-10 in ACC haplotype and low levels of
IL-10 in ATA haplotype.11
The balance between proinflammatory and anti-
inflammatory cytokines is a determinant in the endothelial
dysfunction. Several studies based on invasive12,13 or non-
invasive14 methods revealed evidence that sustains the
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cular risk, in patients without clinical evidence of cardiovas-
cular disease but with risk factors, as well as in patients with
clinical symptoms.
Aim. This study evaluates the association between
proinflammatory IL-6 and anti-inflammatory IL-10 gene
promoter polymorphisms and the short-term (30 days) risk
of acute postoperative cardiovascular events in patients with
PAD receiving elective surgical revascularization. We also
studied the prognostic role of noninvasive endothelial dys-
function assessment (flow-mediated dilation [FMD]) on
the brachial artery in the appreciation of short-term risk of
cardiovascular events in these patients and the influence of
IL-6 and IL-10 gene polymorphism upon endothelial func-
tion estimated by ultrasonography with brachial artery
FMD.
METHODS
Studied population. This prospective cohort study
was conducted on 48 consecutive patients (Caucasians)
with PADFontaine stage II B–IV, which were submitted to
peripheral elective surgical revascularization in the period
between July 1, 2007 and July 1, 2008. The applied surgi-
cal interventions include aortofemoral bypass, femoropop-
liteal bypass, extra-anatomic (axilofemoral) bypass, and am-
putations. Patients with acute coronary syndrome and/or
stroke within the last 3 months and those with decompen-
sated heart failure, severe renal disease (stages 5 and 6 on
NFK-DOQI classification – GFR below 30 mL/min/1.73
m2 or renal substitution [dialysis]), acute infections, neo-
plasms, and cardiac/vascular interventions within the last 6
months were excluded. In all patients, we performed pre-
operative screening for detecting usual acute infections
(urine sample, urine culture, nasal, and faringian exudate,
thoracic X-ray), and we excluded patients with positive
results (surgical intervention was postponed). The investi-
gation conforms to the principles outlined in the Declara-
tion of Helsinki.
Study protocol. Patients were evaluated preoperatively
by anamnesis (medical history of coronary disease: myocardial
infarction, angina pectoris, coronary lesions; cerebrovascular
disease: stroke, carotid lesions; the presence of renal failure;
presence of risk factors: hypertension, dyslipidemia, diabetes
mellitus, smoking; treatment), clinical examination (blood
pressure, body mass index [BMI], ankle-brachial index
[ABI]), electrocardiogram, echocardiography (left ventricular
ejection fraction [EF]), carotid Doppler exam (intima-media
thickness, carotid lesions), and by laboratory findings (glyce-
mia, lipid profile, renal function, inflammatory factors—
fibrinogen, C-reactive protein, leucocytes). Some of the pa-
tients with high or medium preoperative cardiovascular risk15
were evaluated by coronary angiography. In all studied pa-
tients, the IL-6 gene (-174 G/C and nt565 G/A) and IL-10
gene (-1082 G/C, -819G/C, -592 G/A) promoter poly-
morphism was evaluated preoperatively on peripheral blood.
DNA extracted from peripheral blood was amplified through
polymerase chain reaction (PCR). For genotyping, we used a
5-mL EDTA sample of peripheral blood from which DNAwas extracted by salting aut method. Sequence amplification
was performed by PCRwith primers (sequence-specific prim-
ers [SSP]). Amplificationmix contained dNTP, Taq polymer-
ase, and patient DNA. After amplification, we visualized pres-
ence/absence of a genoype by agarose gel electophoresis.
Endothelial function was evaluated preoperatively in all sub-
jects by endothelium-dependent and independent vasodila-
tion on the brachial artery.
FMD was evaluated noninvasively on the brachial ar-
tery by the method described by Celermajer16-18 with a
Fukuda ultrasound system equipped with a 7.5-MHz linear
array transducer. Patient preparation before evaluation
consisted of fasting and smoking cessation for at least 8
hours before measurements and vasoactive medication in-
terruption for at least 12 hours before measurements. As-
sessment was made at constant temperature (21 2°C), in
supine position, monitoring the electrocardiogram. Mea-
surements weremade on the brachial artery, at about 10 cm
from the elbow crease in longitudinal section. Initially, we
measured endothelium-dependent FMD, which represents
the procentual variation of the end-diastolic diameter of the
brachial artery at 60 seconds after a provoked hyperemia,
obtained by inflating the cuff 50 mm Hg above the
systolic blood pressure value over a period of 5 minutes,
using the cuff of a sphygmomanometer, placed on the
arm (FMD%). After a rest period of at least 10 minutes,
endothelium-independent vasodilation was measured,
which represents the procentual variation of brachial artery
end-diastolic diameter at 4 minutes after sublingual adminis-
tration of nitroglycerin 0.4 (NTG%).
Follow-up for cardiovascular events. Patients were
followed up for acute cardiovascular events over a period of
30 days. These events included cardiovascular death, resus-
citated cardiac arrest (ventricular fibrillation/asystole),
acute myocardial infarction with/without ST-segment ele-
vation, unstable angina, stroke, and coronary/carotid/
peripheral surgical revascularizations. Patients were moni-
tored from the first postoperative day until discharge by
clinical examination, electrocardiogram (on the first and
third postoperative day and at discharge) and by enzymatic
tests—CK, CK-MB, T troponin (on the first and third
postoperative day). After discharge, patients were fol-
lowed up on the phone and by clinical examination and
also by electrocardiogram on the 30th day. The statistic
analysis included a single acute cardiovascular event for
each patient.
Statistic analysis. For statistical analysis, 2 test and
Fisher’s exact test (values 5) were used to compare the
differences between the groups for the dichotomic variables
and factorial analysis of variance (ANOVA) test for the
continuous variables. The results were expressed as the
average value  standard deviation (the difference was
considered significant when the value of probability P was
.05). Also, for the skew-distributed continuous variables,
FMD%, NTG%, fibrinogen, leucocytes, C-reactive protein,
EF, and the Mann-Whitney U test was applied. Cox model
was used to control the potential variables that could create
confusion, and the results were presented as relative risk
dy ma
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compare the observed number of each genotype with that
expected for a population to establish if they were in
Hardy-Weinberg equilibrium. Analysis was performed with
SPSS for Windows, version 10.1.
RESULTS
Studied patients. The following surgical procedures
were performed on the 48 studied patients: aortofemoral
bypass on 15 patients (31.25%); femoropopliteal bypass on
26 patients (54.17%); amputations on 4 patients (8.33%);
and extra-anatomic bypass on 3 patients (6.25%). During
the follow-up period, 8 patients developed cardiovascular
events (16.7%): acute myocardial infarction, 2 patients
(25%); unstable angina, 1 patient (12.5%); stroke, 1 patient
(12.5%); resuscitated cardiac arrest, 2 patients (25%); and
cardiovascular death, 2 patients (25%).
Table I contains the general characteristics of the pa-
tients in accordance with the presence of acute cardiovas-
cular events. Of the inflammation markers, there are signif-
icant differences only between white blood cell count (P
.005) but not in terms of the plasma level of C-reactive
protein or fibrinogen.
There were no statistically significant differences be-
tween the two subgroups regarding the frequency of coro-
nary artery disease and medical history of heart failure and
not even between the frequency of cardiovascular risk fac-
tors (diabetes mellitus, hypertension, dyslipidemia, smok-
ing, age, body mass index). Also, there were no significant
differences in patients with and without cardiovascular
events regarding smoking (75% actual and 25% past smok-
ing vs 62.5% actual, 35% past, and 2.5% never smoked) and
intensity of smoking (28.5 pack year vs 26.7 pack year).
Gene polymorphism. The distribution of genotypes
was in Hardy-Weinberg equilibrium. Within the studied
Table I. Clinical characteristics according to cardiovascula
Parameters No CV events (n 
Age (y) 61.3  8.16
Male sex (%) 82.5
Smoking (%) 97.5
Dyslipidemia (%) 80.0
Hypertension (%) 75.0
Diabetes mellitus (%) 35.0
BMI (kg/m2) 26.08  5.87
ABI 0.43  0.14
Coronary artery disease (%) 15.0
Congestive heart failure (%) 12.5
LV ejection fraction (%) 56.25  7.99
WBC (/mm3) 8021.0  1551
Fibrinogen (mg/dL) 458.08  111.
C-reactive protein (mg/dL) 13.19  6.94
Fontaine stage  III (%) 50
Antiplatelet treatment (%) 100
Statin treatment (%) 62.5
ACE inhibitor treatment (%) 75
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; BMI, bogroup allele frequency of IL-6 – 174 GC genotype was68.7% for allele G and 31.3% for allele C, respectively and
that of nt565 GA genotype was 69.8% for allele G and
30.2% for allele A. Table II shows the studied parameters
according to IL-6 genotypes and IL-10 haplotypes. It is
remarkable that postoperative cardiovascular events were
more frequent, statistically significant, in IL-6 – 174 CC
genotype (P  .007) associated with high serum levels of
IL-6, in nt565 AA genotype (P  .021) and IL-10 ATA
haplotype (P  .004) associated with low serum levels of
IL-10.
Compared with – 174 GG genotype, the relative risk of
cardiovascular events was significantly higher in -174 CC
homozygotes: 2.14 (1.07-5.08), while the GC heterozy-
gotes had a relative risk of 1.05 (0.84-1.13). Regarding the
IL-6 nt565 GA genotype, the relative risk of cardiovas-
cular events was significantly higher in homozygotes AA:
1.84 (1.03-4.13), GA heterozygotes presented a relative
risk of 1.12 (0.87-1.43) compared with GG homozygotes.
Also, there is a significantly higher relative risk in the IL-10
haplotype associated with low serum levels of IL-10 – ATA:
2.16 (1.41-5.11), while at the ACC haplotype associated
with intermediary levels of IL-10, the relative risk was 1.08
(0.85-1.37), compared with haplotypes associated with
high levels of IL-10 (GCC, GCA, GTA, GTC). These
associations remained significant after the adjustment per-
formed in accordance with the risk factors for perioperative
cardiovascular events (medical history of coronary disease,
heart failure, ejection fraction, diabetes mellitus, type of
intervention), with markers of inflammation and body mass
index (for IL-6).
FMD. FMD variation was included in the interval
between 4.87% and 12.5% (average value 8.8%  2.28%),
and the endothelium-independent vasodilation was be-
tween 10% and 20% (average value 14.89%  2.11%).
Patients with cardiovascular events had a significantly lower
nts
s) CV events (n  8 pts) P value
64.0  11.2 .43
100 .21
100 .19
62.5 .88
75.0 .99
25.0 .59
24.5  2.39 .46
0.33  0.08 .089
37.5 .06
25.0 .18
53.75  6.94 .41
9725.0  1367.74 .005
539.5  169.9 .09
19.18  5.72 .36
62.5 .56
100 1
67.5 .79
75 1
ss index; CV, cardiovascular; LV, left ventricle; WBC, white blood cells.r eve
40 pt
.0
03FMD value compared with those without events (6.19% 
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significant differences between the two groups regarding the
value of endothelium-independent vasodilation (14.57% 
0.89% vs 14.95%  2.28%, P  .64) (Fig 1). FMD was
significantly lower in patients with the IL-6 -174CCgenotype
(7.05% 1.49% compared with 8.41% 1.9% for IL-6 -174
GC and 9.42%  2.46% for IL-6 -174 GG, P  .009)
(Fig 2, a), in patients with the IL-6 nt565 AA genotype
(7.14%  1.61% compared with 8.49%  1.91% for IL-6
nt565 GA and 9.42%  2.46% for IL-6 nt565 GG, P 
.018) (Fig 2, b), and in patients with the IL-10 ATA
haplotype (6.45%  0.57% vs 9.13%  2.52% for IL-10
ACC and 9.24%  2.09% for IL-10 GCC, GCA, GTA,
GTC, P  .004) (Fig 2, c).
DISCUSSION
The present study relies on the hypothesis that gene
IL-6 -174 GC and nt565 GA polymorphism (with
proinflammatory effect) and gene IL-10 -1082 GC, -819
CT and – 592CApolymorphism (with anti-inflammatory
effect) are associated with short-term acute postoperative
cardiovascular events in patients with PAD submitted to
peripheral elective surgical revascularization. The results
show that the homozygotes of gene IL-6 – 174 CC have a
high risk of postoperative acute cardiovascular events (rel-
ative risk of 2.14 compared with IL-6 -174 GG homozy-
gotes). These data are concordant with the facts demon-
strated by Jones et al in the UK Small Aneurysm Trial.8 In
Table II. Characteristics and IL-6 and IL-10 genotypes
Parameters GG
Serum IL level 2
Genotype frequency (%) 52.1
Fibrinogen (mg/dL) 472.64  111.18
C-reactive protein (mg/dL) 13.66  7.76
BMI (kg/m2) 26.05  6.51
FMD (%) 9.42  2.46
NTG (%) 15.22  2.3
CV events (%) 8
Genotype IL-6 nt 565
P valueGG GA AA G
2 21 1
52.1 35.4 12.5
472.6  111.2 460.1  125.5 500.2  185.0 .8
13.66  7.76 15.22  7.55 13.41  5.21 .95
26.04  6.51 26.24  4.49 23.67  2.42 .59
9.42  2.46 8.49  1.91 7.15  1.62 .018
15.22  2.3 14.44  1.82 14.76  2.15 .5
8 17.6 50 .021
BMI, Body mass index; CV, cardiovascular; FMD, endothelium-depende
nitroglycerine.
1  High.
2  Low.
12  Intermediate.this respect, literature often shows discordant data: someauthors demonstrate the association between CC genotype
and the risk of cardiovascular mortality8 or the risk of
coronary or carotid disease,19 while others associate CG
genotype with a high risk of cerebral vascular accident.20
Humphries et al mention a higher risk of coronary disease
in healthy – 174 GC heterozygotes, compared with GG
homozygotes GG, against –174 CC homozygotes. Also,
there are discordant data regarding IL 6 – 174 GC gene
promoter polymorphism and plasma levels of IL-6: Brull et
al shows that after an acute intervention as an aortocoro-
nary intervention, the plasma level of IL-6 is higher in – 174
CC homozygotes,5 the same as data from the UK Small
Aneurysm Trial, in contradiction to the results of other
studies, which show that there is a higher IL plasma level
found in – 174 GG healthy homozygotes (Fishman et al)21
or that there is no significant association between – 174
GC polymorphism and the IL-6 level (Lu Qi et al) in
patients with type 2 diabetes mellitus and in healthy sub-
jects.22 A possible explanation of these contradictions can
be formulated through the heterogenicity of the different
studied groups, which vary widely from in vitro models to
healthy subjects, patients with rheumatoid arthritis, pulmo-
nary tuberculosis, bronchial asthma, renal transplant or
patients with cardiovascular disease: coronary disease, aor-
tic aneurysm, stroke or, as in the present study, patients
with PAD and an acute injury (surgical revascularization).
An other explanation could be related to the difference
between our study and others, in terms of the C allele
enotype IL-6 -174
P valueGC CC
21 1
33.3 14.6
467.4  125.8 477.7  179.1 .98
15.77  7.97 12.4  5.57 .89
26.31  4.63 23.86  2.86 .59
8.61  1.9 7.05  1.49 .009
14.43  1.88 14.74  1.96 .505
12.5 57.14 .007
Haplotype IL-10
P valueCA/GTA/GTC ACC ATA
1 21 2
56.2 29.2 14.6
.3  122.14 471.3  126.5 504.14  142.54 .75
7  7.28 12.9  5.66 18.72  8.38 .74
96  5.49 26.5  4.74 27.71  6.78 .43
24  2.09 9.13  2.52 6.45  0.57 .001
53  1.84 15.37  2.8 14.89  2.11 .49
7.4 14.28 57.14 .004
w mediated dilatation; NTG, endothelium-indepedent vasodilatation toG
CC/G
463
13.6
24.
9.
14.
nt flofrequency (31.3% vs 40% Jones et al and 40.3% Fischman et
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genotype is similar (14.6% vs 11%) (Fischman).
Furthermore, we cannot exclude the possibility that the
concomitant genetic polymorphism of more proinflamma-
tory cytokines and markers of inflammation (known to be
associated with cardiovascular disease [polymorphism of C-
reactive protein gene, fibrinogen, von Willebrand factor, etc])
interacts on the plasma levels of cytokines and the cardiovas-
cular risk, as a balance between proinflammatory and anti-
inflammatory cytokines in the different studied groups. As a
novel element, the present study offers data regarding
polymorphism of position nt565 GA of gene IL-6, which
shows a significant association with the risk of acute cardio-
vascular events in genotypes with lower frequency of –
nt565 AA (relative risk 1.84), but the risk is lower than in
the -174CC genotype. However, it is difficult to formulate
a conclusion in this regard, considering the low number of
the studied patients and cardiovascular events. Also, rela-
tion between nt565 GA polymorphism and plasma levels
of IL-6 still require evidences if AA homozygotes associate
with a high serum level of IL-6, as we would expect, and if
the association between the polymorphism of IL-6 –174
GC and nt565 G A raises more the cardiovascular risk.
Regarding the IL-10 gene polymorphism, with anti-
inflammatory effect, our study shows a high risk of cardio-
vascular events (relative risk – 2.16) in patients with ATA
haplotype, associated in the literature with low levels of
IL-10, compared with GCC/GCA/GTA/GTC haplo-
types, associated with high plasma levels of IL-10.
There is little evidence in the literature regarding the
association between IL-10 -1082 GA, -819 CT and –
592 CA gene promoter polymorphism, risk of cardiovas-
cular disease, and acute cardiovascular events, although
there are a lot of studies that demonstrate a protective effect
of the high serum levels of IL-10, in vitro and as well in
vivo.23-25 The correlation of – 1082 AA genotype (associ-
Fig 1. Endothelium and nonendothelium-dependendent dilata-
tion and cardiovascular events.ated with low levels of IL-10) was proved with the highprevalence of atherosclerosis in hemodialyzed patients26
and with the high prevalence of renal artery stenosis,27 but
these researches evaluated the polymorphism of a single
locus in IL-10 -1082G/A gene promoter.
Surprisingly, no association was found between IL-6
genotype, C-reactive protein, and fibrinogen (IL-6 is a
major regulator of the hepatic acute phase protein synthe-
sis); a possible explanation is the high number of patients in
stages III and IV Fontaine, with intense inflammatory
activation. However, a significantly lower value of FMD
was demonstrated in –174 CC and nt565 AA homozygotes
and inpatientswith IL-10ATAhaplotype, suggesting that the
balance between proinflammatory and anti-inflammatory cy-
tokines is a major determinant of the endothelial dysfunction.
Studying the endothelium-dependent vasoreactivity (on ace-
tylcholine) and endothelium-independent vasoreactivity (so-
dium nitroprussiate) with forearm plethysmography, Fich-
tlscherer et al showed that the serum level of IL-10 is an
independent predictor of endothelium-mediated vasodila-
tor response in patients with coronary artery disease.28
Also, our results show that low FMD values correlate with
a high risk of short-term acute postoperatory cardiovascular
events in patients with PAD submitted to surgical revascu-
larization. Similar results were reported by Gokce et al,
which demonstrate the role of FMD for the prognosis of
short-term postoperative and long-term postoperative
events in patients with PAD,29,30 and also by Brevetti et al,
who proved the relation between FMD value, the presence
of inflammation, and peripheral atherosclerotic disease ex-
tension in patients with PAD—patients in stage II B Fon-
taine, without peripheral revascularization.31,32
In our study, among the markers of inflammation, just
the leucocyte count proved to be a prognostic factor for
cardiovascular events, while the plasma level of fibrinogen
and C-reactive protein had no statistical significance, al-
though there were quantitative differences between the
two groups in favor of patients with cardiovascular events.
Endothelial dysfunction, which is involved in athero-
sclerotic lesion development and progression and also in
acute cardiovascular event precipitation, is presently associ-
ated by several studies with the traditional and novel risk
factors (smoking, hypercholesterolemia, hypertension, dia-
betes mellitus and homocysteinemia, obesity, and inflam-
mation), as well as with the individual susceptibility, includ-
ing genetic factors.
The main limitation of this study is the small number of
patients and the possibility that the influence of some
characteristics (especially history of coronary artery disease
and congestive heart failure) on risk of acute cardiovascular
events to be underestimated. But in the subgroups of IL-6
and IL-10 genotypes/haplotypes, there were not signifi-
cant differences regarding coronary artery disease and heart
failure history. Also, at multivariate analysis (considering
coronary artery disease and heart failure, too) the associa-
tion of IL-6 and IL-10 polymorphism and acute cardiovas-
cular events remained significant.
Although the present study was conducted on a small
group of patients, it offers evidence that sustains the asso-
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polymorphism of the proinflammatory (IL-6) and anti-
inflammatory interleukins (IL-10) keeping in sight that
inflammation is one of the most powerful determinants of
the endothelial dysfunction. As a conclusion of this study,
we can say that -174 CC genotype, correlated by the
literature with high serum levels of IL-6 and with proin-
flammatory effect and nt565 AA genotype is associated
with a short-term high risk for postoperative cardiovascular
events in patients with PAD submitted to elective surgical
revascularization. Also, IL-10 ATA haplotype, correlated
by the literature with low levels of anti-inflammatory IL-10
is associated with a high risk of cardiovascular events in
these patients. Endothelial dysfunction, noninvasively ap-
preciated by FMD on the brachial artery represents an
important predictor for short-term postoperative cardio-
vascular events. Determination of more endothelial dys-
function parameters improves the algorithm of preopera-
tive assessment in patients with PAD, with the possibility of
identifying patients with very high risk of postoperative
Fig 2. FMD variation according to IL-6 and IL-10 ge
genotype. c, IL-10 genotype.acute cardiovascular events.AUTHOR CONTRIBUTIONS
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